Anti-inflammatory Disease Therapies
Sarah Bolton(AstraZeneca (United Kingdom)), Aude Roulois(GlaxoSmithKline (United Kingdom)), Jeffrey K. Huang(Georgetown University), Joel D. Parry(Age UK), Dave Hassall(GlaxoSmithKline (United Kingdom)), Rajni Fagg(GlaxoSmithKline (United Kingdom)), Mary McFarlane, Tom P. McKevitt(GlaxoSmithKline (United Kingdom)), Stefano Pluchino(University of Cambridge), Deon Hildebrand(GlaxoSmithKline (United Kingdom)), Wolfgang Brück(Universitätsmedizin Göttingen)
Cited by 2
Related Papers
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
|Brain|2007|714
Macrophage-Derived Extracellular Succinate Licenses Neural Stem Cells to Suppress Chronic Neuroinflammation
|Cell stem cell|2018|271
Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons
|Acta Neuropathologica|2013|213